At 1:59 PM EST on September 27, 2024, Allogene Therapeutics, Inc. (ALLO, Financial) experienced a significant stock price increase of 5.15%. The stock is currently priced at $2.86 per share, with a trading volume of 536,668 shares and a turnover rate of 0.26%. The stock's amplitude is 3.49%.
Recent financial reports show that the company generated no revenue, had a net loss of $66.36 million, and an earnings per share (EPS) of -$0.35. The gross loss stood at $3.64 million, and the price-to-earnings (P/E) ratio was -1.78.
Among the 18 institutions that rated the stock, 72% recommended buying, while 28% suggested holding, with none advising to sell.
In the biotechnology sector, where Allogene Therapeutics Inc. operates, the overall decline was 0.41%. Comparable stocks such as Nls Pharmaceutics Ltd, Onconetix, Inc., and Psyence Biomedical Ltd saw significant gains. Stocks like Onconetix, Inc., Seelos Therapeutics, Inc., and Tonix Pharmaceuticals Holding Corp. were notably active, with turnover rates of 4353.44%, 269.32%, and 138.47% respectively. Stocks with significant amplitude included Pasithea Therapeutics Corp, Estrella Immunopharma Inc, and others.
Allogene Therapeutics Inc. is a clinical-stage biotechnology company focused on developing genetically engineered allogeneic T cell products for cancer and autoimmune diseases. Their product pipeline includes ready-to-use T cell candidates targeting cancer and self-reactive cells in autoimmune diseases. The company aims to redefine CAR T therapy, concentrating on lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue is mainly derived from partnerships and licensing agreements supporting their R&D efforts.
